about
Bile acid transporters in health and diseaseAltered aquaporin 9 expression and localization in human hepatocellular carcinoma.Inspissated bile syndrome in an infant with citrin deficiency and congenital anomalies of the biliary tract and esophagus: identification and pathogenicity analysis of a novel SLC25A13 mutation with incomplete penetrance.Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modificationsPrediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump.Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorptionOST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids.Physiology of bile secretion.Dynamic localization of hepatocellular transporters in health and disease.Novel ABCB11 mutations in a Thai infant with progressive familial intrahepatic cholestasis.Oxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system.Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors.Physiological and molecular biochemical mechanisms of bile formation.New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.Identification of functionally relevant lysine residues that modulate human farnesoid X receptor activation.Genetic variants associated with gastrointestinal symptoms in Fabry disease.How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion.Growth and development of a new subspecialty: pediatric hepatology.Improved microcirculation by low-viscosity histidine- tryptophan-ketoglutarate graft flush and subsequent cold storage in University of Wisconsin solution: results of an orthotopic rat liver transplantation model.Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2.A more accurate profile of Achyrocline satureioides hypocholesterolemic activity.
P2860
Q24647024-2F83FE86-6708-42BB-828B-6EC613526646Q27967656-295E8E17-986B-4C94-9A4C-7858D5F7E8CCQ34350319-15D49C4C-DF55-468E-AF1D-B6E7583AFA34Q34694229-B7719CC5-3447-46F6-97B1-2D7D15AC829DQ36689081-0E6EDE5F-DA12-4CCE-A252-F0DBE063EBC2Q37188010-BBC09027-1301-442B-96BC-4301F7C8F9BAQ37222442-96B57576-F6D6-4B34-AFB6-443EB66615C9Q37287602-ADBBF1B9-2FD5-4622-B209-506A96A01130Q37341910-676D6579-252D-41EB-ACC5-5C66C7CD9F64Q37347363-BB62DA1E-85FD-47B4-BD69-15B42858D498Q37638753-B01A168A-4B47-4719-BB47-CB909D792DADQ38009566-5DD0CB49-305E-428A-B47C-F854717FCB10Q38164702-2C555FD8-9A1F-45A8-BE57-5B00067D7B38Q38266172-31DE3683-D3F7-4C1E-8B6C-E1F8C982F680Q41943299-3857BB69-C8C1-4BED-81A5-F0189DFD19D7Q42316513-5FBC97C8-AB1E-4C83-A728-275FB678E88EQ42561623-986891C2-E46D-4D63-B571-D3EA154980B3Q46062037-C423B210-D416-4BCA-A78E-322E3CA26D36Q46432349-3CF30755-2EAC-4036-889A-66DBD95EE8E7Q50973887-77A5D499-5693-456C-B9AA-D7277160446FQ53183837-B00B84A3-3F2C-47C2-BB5F-A3603B9AB20C
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bile salt excretory pump: biology and pathobiology.
@ast
Bile salt excretory pump: biology and pathobiology.
@en
type
label
Bile salt excretory pump: biology and pathobiology.
@ast
Bile salt excretory pump: biology and pathobiology.
@en
prefLabel
Bile salt excretory pump: biology and pathobiology.
@ast
Bile salt excretory pump: biology and pathobiology.
@en
P1476
Bile salt excretory pump: biology and pathobiology.
@en
P2093
Frederick J Suchy
M Ananthanarayanan
P356
10.1097/01.MPG.0000226385.71859.5F
P407
P478
43 Suppl 1
P577
2006-07-01T00:00:00Z